Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.16 and traded as high as $1.87. Cortexyme shares last traded at $1.73, with a volume of 218,043 shares.
Cortexyme Stock Down 3.4 %
The stock’s fifty day simple moving average is $1.87 and its two-hundred day simple moving average is $1.17. The firm has a market cap of $52.16 million, a PE ratio of -0.58 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- P/E Ratio Calculation: How to Assess Stocks
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- How to Use the MarketBeat Excel Dividend Calculator
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Ride Out The Recession With These Dividend Kings
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
